[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laboratoires Thea\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":210},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,60,98,121,147,171,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100584599","phase-3-study-to-evaluate-sepofarsen-in-subjects-with-leber-congenital-amaurosis-lca-type-10-hyperion-100584599",false,"NCT06891443","Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)","A Double-Masked, Randomized, Placebo-Controlled, Paired-Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene","HYPERION","Inclusion Criteria:\n\n1. Confirmed clinical diagnosis of LCA10 and a molecular diagnosis of homozygosity or compound heterozygosity for the c.2991+1655A\\>G mutation in CEP290.\n2. Adults: \\>=18 years \u002F Minors: 6 to \\\u003C18 years.\n3. BCVA (FrACT) equal to or worse than logMAR +0.4 (approximate Snellen equivalent 20\u002F50) to +2.9 logMAR based on quantifiable, reliable FrACT. LP subjects with documented evidence of prior better vision eligible.\n4. Symmetrical disease between the two eyes as defined by a BCVA (FrACT) within 0.2 logMAR at baseline.\n5. Detectable ONL in the macular area as determined by the CRC at Screening.\n\nExclusion Criteria:\n\n1. Mutations in genes other than the CEP290 gene associated with other IRD diseases or syndromes.\n2. Presence of any ocular pathology in either eye that may make comparison of the eyes not feasible.\n3. Presence of unstable concurrent CME, or subject started on (or changed dose of) topical or systemic carbonic anhydrase inhibitor treatment in the 3 months prior to enrollment. CME is allowed if stable for 3 months (with or without treatment).\n4. Presence of any clinically significant lens opacities\u002Fcataracts based on the AREDS lens grading scale.\n5. Any prior receipt of genetic (RNA or DNA therapy) or stem-cell therapy for ocular or non-ocular disease, including sepofarsen.","ALL","6 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\\>G (p.Cys998X) mutation in the CEP290.",[27,28,29,30,31,32,33,34,35,36],"Leber Congenital Amaurosis 10","Blindness","Leber Congenital Amaurosis","Sensation Disorders","Vision Disorder","Neurological Manifestations","Eye Diseases, Hereditary","Eye Diseases","Eye Disorders Congenital","Retinal Disease",[38,39,40,41,42,43,44,45,46],"LCA10","p.Cys998X","Antisense oligonucleotides","RNA therapy","QR-110","sepofarsen","CEP290","Leber's Congenital Amaurosis","c.2991+1655A>G","RECRUITING","2026-06-24",{"date":50,"type":51},"2026-06-25","ACTUAL",{"date":53,"type":51},"2025-06-04",{"date":55,"type":21},"2028-10",{"name":57,"class":58},"Laboratoires Thea","INDUSTRY",17,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":79,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100564284","phase-2-study-to-evaluate-ultevursen-in-subjects-with-retinitis-pigmentosa-rp-due-to-mutations-in-exon-13-of-the-ush2a-gene-100564284","NCT06627179","Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","LUNA","Inclusion Criteria:\n\n1. An adult (≥18 years) willing and able to provide informed consent for participation prior to performing any study related procedures\n2. OR A minor (8 to \\\u003C18 years) able to provide age-appropriate assent for study participation with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures. An adult willing to comply with the protocol, follow study instructions, attend study visits as required and willing and able to complete all study assessments, in the opinion of the Investigator.\n\n   OR A minor able to complete all study assessments and comply with the protocol and has a parent or caregiver willing and able to follow study instructions and attend study visits with the subject as required, in the opinion of the Investigator.\n3. Both eyes exhibit clinical presentation consistent with RP involving Usher syndrome type 2 or NSRP based on ophthalmic, audiologic, or vestibular examinations. At screening, the Investigator will make the clinical diagnosis of \"Usher syndrome type 2a,\" defined as RP with congenital hearing loss, or \"non-syndromic RP,\" defined as RP without congenital hearing loss.\n4. A molecular diagnosis of biallelic disease causing variants (pathogenic or likely pathogenic) in the USH2A gene where at least one of the variants is located on exon 13. A historic genotyping report from a certified laboratory is acceptable with Sponsor approval.\n5. Clearly visible and measurable SD-OCT horizontal EZ width of ≥2.2 mm in both eyes based on the assessment of the CRC.\n6. BCVA ≥55 letters based on ETDRS (equivalent to 20\u002F80 based on Snellen notation, or logarithm of the minimum angle of resolution \\[logMAR\\] +0.6) in both eyes.\n7. Impairment of VF as assessed by SP with a mean sensitivity greater than 4 decibels (dB) and less than 25 dB measured by a V target size in the TE at screening.\n8. Mean sensitivity greater than 2 dB as determined by MP in the TE at screening.\n9. Symmetry of baseline disease in both eyes, defined as the mean BCVA (based on ETDRS) of one eye within ≤10 letters of the mean BCVA of the other eye at screening.\n\nExclusion Criteria:\n\n1. Presence of additional non-exon 13 USH2A pathogenic or likely pathogenic variant on the USH2A allele carrying the exon 13 mutation in subjects who have one exon 13 disease causing variant and one non-exon 13 disease causing variant.\n2. Presence of additional non-exon 13 USH2A pathogenic mutation(s) on both USH2A alleles in subjects who have biallelic exon 13 mutations.\n3. Presence of pathogenic or likely pathogenic variants in genes (other than the USH2A gene) which are known to be associated with other inherited retinal degenerative diseases or syndromes. Specifically, the presence of homozygous or compound heterozygous known disease-causing mutations in other genes involved in recessive retinal dystrophies, or the confirmed presence of a known single disease-causing variant in genes involved in dominant, X-linked, or mitochondrial retinal dystrophy genes is exclusionary.\n4. At screening, the EZ horizontal or vertical width are outside the field of the SD-OCT scan based on the assessment of the CRC.\n5. Presence of any significant ocular or non-ocular disease\u002Fdisorder (including medication and laboratory test abnormalities) which, in the opinion of the Investigator may either put the subject at risk because of participation in the study, may impact the subject's ability to participate in the study, or may interfere with assessment of efficacy and safety in the study.\n6. Presence of unstable concurrent cystoid macular edema (CME), or subject started on (or changed dose of) any medication for CME in the 3 months prior to enrollment. CME is allowed if stable for 3 months (with or without treatment). However, stable CME that disrupts the EZ width measurement, as determined by CRC, is an exclusion.\n7. Any intraocular surgery within 3 months of study entry or any planned intraocular or peri-ocular surgery during the study. Subjects may be eligible after 3 months post-surgery as long as they have fully recovered, in the opinion of the Investigator.\n8. Receipt of any IVT injection prior to study entry.","8 Years",{"count":70,"type":21},81,[72],"PHASE2","The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.",[75,76,77,36,33,35,78],"Retinitis Pigmentosa (RP)","Usher Syndrome Type 2","Deaf Blind","Vision Disorders",[80,76,77,81,82,83,84,85,86,66,87,88],"Retinitis Pigmentosa","USH2A","RP","Exon 13","RNA therapies","antisense oligonucleotide","exon skipping","IVT","NSRP","2026-06-16",{"date":91,"type":51},"2026-06-18",{"date":93,"type":51},"2024-12-11",{"date":95,"type":21},"2027-12",{"name":57,"class":58},28,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100610954","evaluation-of-patient-satisfaction-with-blephaderm-as-a-complementary-care-in-post-eyelid-surgery-100610954","NCT07234292","Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery","Evaluation of Patient Satisfaction With a New Preservative-free Eyelid Cream as a Complementary Care in Post-eyelid Surgery: The ADMIRE Study","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patients planning a blepharoplasty or a ptosis surgery in at least one eye.\n* Patient affiliated to a health social security system\n* Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.\n\nExclusion Criteria:\n\nIn terms of population:\n\n* Pregnant or nursing woman or planning a pregnancy during the study.\n* Patient who had been deprived of their freedom by administrative or legal decision\n* Minor patient.\n* Major patient who is under guardianship or who is not able to express his non opposition.\n* Patient suspected to be non-compliant according to the investigator's judgment.\n* Patient enrolled in another clinical trial or which exclusion period is not over.\n\nIn terms of associated pathology\n\n* Patient with a history or active systemic condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk.\n* Patient suffering from a severe or progressive disease.\n* Patient with known or suspected hypersensitivity to one of the components of the product.\n\nRelated to previous or ongoing treatment\n\n* Patient undergoing a topical treatment on the test area or a systemic treatment.\n* Patient under a long-term corticosteroid, NSAID or HIV therapy at the investigator appreciation.\n* Patient under immunosuppressive therapy\n* Patient under bisphosphonate therapy\n* Patient having Type 1 diabetes\n* Patient having atopic or eczema skin\n\nIn terms of lifestyle\n\n* Intensive exposure to sunlight or UV-rays foreseen during the study.\n* Patient planning to change her\u002Fhis life habits during the study.\n* Patient with an excessive consumption of alcohol and\u002For tobacco defined as:\n* an excessive consumption of alcohol: Drinking more than\n* 4 units a day for adult men and more than 2 units a day for adult women,\n* an excessive consumption of tobacco: ≥15-20 Cigarettes Per Day (CPD).","18 Years",{"count":107,"type":21},30,"OBSERVATIONAL","The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis).\n\nThe participant will be asked to use Blephaderm twice a day. The patient satisfaction will be evaluated using a VAS scale.",[111],"Eyelid; Wound","2026-04-28",{"date":114,"type":51},"2026-05-04",{"date":116,"type":51},"2025-10-30",{"date":118,"type":21},"2026-12-15",{"name":57,"class":58},1,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100605988","phase-2-a-study-to-compare-the-effectiveness-and-safety-of-t1695-versus-ciclosporin-in-participants-with-moderate-to-severe-vernal-keratoconjunctivitis-100605988","NCT07169695","A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","Efficacy and Safety Assessment of T1695 Ophthalmic Suspension, Versus Ciclosporin Ophthalmic Emulsion, in Participants With Moderate to Severe Vernal Keratoconjunctivitis (VKC)","Main Inclusion Criteria:\n\n* Informed consent signed and dated\n* Male or female participant from 4 years to less than 18 years old.\n* Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.\n\nMain Exclusion Criteria:\n\nParticipants must not have any conditions which might exclude them from participating, could interfere with the study, or pose an unacceptable risk to their health.","4 Years","17 Years",{"count":131,"type":21},120,[72],"The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis",[135],"Moderate to Severe Vernal Keratoconjunctivitis",[137],"Vernal Keratoconjunctivitis","2026-04-21",{"date":140,"type":51},"2026-04-22",{"date":142,"type":51},"2026-03-24",{"date":144,"type":21},"2027-01-21",{"name":57,"class":58},11,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},"100633096","phase-2-safety-and-efficacy-of-t10430-eye-drops-in-controlling-paediatric-myopia-progression-100633096","NCT07522242","Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression","Principal Inclusion Criteria:\n\n1. \\- Informed consent signed and dated.\n2. \\- Male or female participant between ≥ 6 and \\\u003C 12 years old.\n3. \\- Spherical equivalent refractive error (SER) of at least -1.00D and no more than -6.00D in each eye as measured by cycloplegic autorefraction.\n4. \\- IOP \\\u003C 21mmHg in each eye.\n5. \\- Distant BCVA equal or better than 0.1 LogMAR \\[≤ 0.1 LogMAR (equivalent to ≥ 20\u002F25 Snellen)\\] in each eye.\n\nPrincipal Exclusion Criteria:\n\nOphthalmic exclusion criteria in AT LEAST ONE EYE (1-11):\n\n1. Known intolerance to administration of eye drops.\n2. Astigmatism \\> 1.50D as measured by cycloplegic autorefraction.\n3. Anisometropia ≥ 1.50D as measured by cycloplegic autorefraction.\n4. Current or history of amblyopia or manifest strabismus including intermittent tropia.\n5. Current or history of glaucoma.\n6. Current or history of significant or severe damage to the cornea.\n7. Presence of anterior segment pathology (e.g. iris malformation, cataract).\n8. Presence of posterior segment or retinal pathology (dystrophies).\n9. History of any disease or syndrome that predisposed the participant to severe myopia (e.g., Marfan syndrome, Stickler syndrome, retinopathy of prematurity).\n10. History of non-axial cause of myopia (refractive or secondary myopia).\n11. History of abnormal ocular refractive anatomy (e.g., keratoconus, keratoglobus, lenticonus, spherophakia).\n\nSystemic\u002Fnon-ophthalmic exclusion criteria (12-13):\n\n12 - Known or suspected hypersensitivity to one of the components of the IMP (T10430) or diagnostic agents used during the study (e.g., fluorescein, cycloplegic agent).\n\n13- History of or active relevant systemic condition (e.g., connective tissue disease, allergy) incompatible with the study or likely to interfere with the study results or the participant safety according to investigator's judgment.\n\n14- Specific exclusion criteria regarding sexually active individuals (14-15): Pregnancy for post-menarche participant (confirmed with a positive urine pregnancy test).\n\n15- Adolescent of childbearing potential (male\u002Ffemale) who is sexually active and is not willing to use preventive measures.\n\nExclusion criteria related to general conditions (16-21):\n\n16- Inability of participant and\u002For legal guardian(s) to understand the study procedures or to give informed consent.\n\n17- Non-compliant participant and\u002For legal guardian(s) (e.g., not willing to attend a visit or a phone call or to complete the diary, way of life interfering with compliance).\n\n18- Participation in this study at the same time as another clinical study. 19- Participation in this study within the 4 weeks after the end of a previous clinical study not related to myopia (or within 5 half-lives of the previously tested product if longer than 4 weeks).\n\n20- Participant previously randomised in this study. 21- Participant being family member of the study sites or of the Laboratoires Théa company.\n\n22- Exclusion criteria related to previous and concomitant treatments (medications\u002Fnon-medicinal therapies\u002Fprocedures): Participant with previous, current or anticipated prohibited listed treatment (or prohibited modification of treatment regimen).","11 Years",{"count":155,"type":21},200,[72],"Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry. Axial myopia tends to start during childhood and worsens over time (as the eyes continue to grow longer). This can lead to serious eye-related conditions later in life. The aim of T10430 treatment is to stop or slow this progression during childhood and therefore, prevent more serious complications. Animal studies using drugs with a similar mechanism of action as T10430 have demonstrated positive safety results. This study aims to better understand the safety and potential effectiveness of T10430 in children with axial myopia.",[159],"Myopia",[161],"Paediatric myopia","2026-04-03",{"date":164,"type":51},"2026-04-13",{"date":166,"type":51},"2026-01-21",{"date":168,"type":21},"2027-11",{"name":57,"class":58},10,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":59},"100608828","real-world-study-to-assess-adherence-to-iop-lowering-therapy-in-glaucoma-patients-using-connectdrop-100608828","NCT07206628","Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®","Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®: the GRANITE Study (Glaucoma tReatment AdhereNce wIth connecTed dEvice in Italy)","Inclusion Criteria:\n\n* Adult patient (≥ 18 years old), man or woman\n* Patient with a diagnosis of bilateral open angle glaucoma\n* Patients being prescribed with glaucoma eye drops in EASYGRIP® bottle for at least 6 weeks in monotherapy.\n* Patient willing to participate in the study\n* Patient who consents for data collection in the frame of the study\n\nExclusion Criteria:\n\n* Pregnant and\u002For lactating woman\n* Patient receiving another ocular treatment for a chronic condition (i.e. regular instillations for several months)\n* Protected patient: adult under guardianship, curatorship or other protection legal, deprived of liberty by judicial or administrative decision",{"count":155,"type":21},"The goal of this real-life, national, multicentre, prospective clinical investigation is to describe the adherence rate over time in patients with glaucoma already treated with IOP-lowering eye drops using connected device CONNECTDROP®\n\nThe main questions it aims to answer are:\n\n* The mean annual adherence rate, defined as the percentage of the prescribed doses taken by the patient\n* The adherence profile of each patient\n* The association between the adherence profile, the objective adherence data and the clinical data.\n\nParticipants will use the connected device CONNECTDROP® associated with the smartphone application on a daily basis.",[181],"Adherence to Glaucoma Therapy","2025-11-14",{"date":184,"type":51},"2025-11-17",{"date":186,"type":51},"2025-09-19",{"date":188,"type":21},"2027-03",{"name":57,"class":58},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":120},"100585544","phase-4-new-preservative-free-combination-of-trehalose-sodium-hyaluronate-and-n-acetyl-aspartyl-glutamate-naaga-in-dry-eye-100585544","NCT06903741","New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye","Effect of a New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) on Dry Eye Disease and Patient Quality of Life","Inclusion Criteria:\n\n* Men and women aged over 18 years,\n* Able to give written informed consent prior the initiation of any procedure,\n* History of dry eye syndrome for at least 3 months,\n* OSDI ≥13,\n* Never been treated with artificial tears or with no artificial tears at least 1 month before the enrolment, or not satisfied with current artificial tears.\n\nExclusion Criteria:\n\nSystemic\u002Fnon Ophthalmic Exclusion Criteria\n\n* Known or suspected hypersensitivity to one of the components of the IMD,\n* History of or active relevant systemic condition incompatible with the investigation or likely to interfere with the investigation results or the patient safety according to investigator judgment.\n\nSpecific Exclusion Criteria Regarding Childbearing Potential Women\n\n* Pregnant or breast-feeding women,\n* Childbearing potential women neither surgically sterilised nor using an adequate contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch) .\n\nExclusion Criteria Related to General Conditions\n\n* Alcohol addiction and heavy smoker according to investigator's judgement,\n* Unable to understand the investigation procedures or to give informed consent,\n* Non-compliant (e.g., not willing to attend a visit or completing the self-questionnaire; way of life interfering with compliance),\n* Participant in this investigation at the same time as another clinical investigation\u002Fstudy,\n* Participant in this investigation within the exclusion period of a previous study\u002Finvestigation with a minimum of one month,\n* Participant being institutionalized because of legal or regulatory order, inmate of psychiatric wards, prison or state institutions, or employee or family member of the investigation sites or of the Sponsor's company.\n\nExclusion criteria related to previous and concomitant treatments (medications\u002Fnon-medicinal therapies\u002Fprocedures)\n\n• Participant with previous, current or anticipated prohibited listed treatment (or prohibited modification of treatment regimen).",{"count":107,"type":21},[199],"PHASE4","The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30 patients having dry eye disease.\n\nThe main questions it aims to answer are:\n\n* To assess the performance and safety of T2769 at 3 months and 6 months.\n* To assess patient compliance to therapy.\n* To assess the occurrence of dry eye flares. Participants will be asked to use T2769 on a daily basis and complete a self-questionnaire throughout the study.",[202],"Dry Eye Disease (DED)",{"date":204,"type":51},"2025-11-18",{"date":206,"type":51},"2025-10-21",{"date":208,"type":21},"2026-06",{"name":57,"class":58},""]